Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Zymeworks Inc.

Get SEC filing alerts via email and in your feed for Zymeworks Inc.

ZYME

Zymeworks Inc.

About Zymeworks Inc.

Zymeworks Inc. is a biotechnology company specializing in developing multifunctional, antibody-based therapeutics for cancer and autoimmune diseases. Its platforms enable precise engineering of bispecific, multispecific, and antibody-drug conjugates. The company partners globally to advance innovative treatments, leveraging proprietary technologies to address unmet medical needs and generate revenue through licensing, milestone payments, and royalties. Its pipeline includes clinical and preclinical candidates targeting high-value cancer indications.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Zymeworks Inc.

1
1
Zymeworks Inc. Zymeworks Reports 91% Revenue Decline and $44.2 Million Net Loss in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Zymeworks Inc. Zymeworks Reports $81.1 Million Net Loss and $106 Million Revenue in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Zymeworks Inc. Zymeworks Reports 73% Revenue Growth to $27.6 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Zymeworks Inc. Zymeworks Reports 154% Revenue Increase to $48.7 Million in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Zymeworks Inc. Zymeworks Reports 171% Revenue Increase to $27.1 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Zymeworks Inc. Zymeworks Reports $122.7 Million Net Loss for 2024, Revenue Increases to $76.3 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Zymeworks Inc. Zymeworks Reports Decrease in Revenue, Net Loss in Latest Quarter, Shifts Focus to Early-Stage Product Candidates

Via official filing (AI summary) | over 1 year ago | 0 comments